Medtronic, Minneapolis, MN, USA.
Medtronic, Minneapolis, MN, USA.
Parkinsonism Relat Disord. 2023 May;110:105364. doi: 10.1016/j.parkreldis.2023.105364. Epub 2023 Mar 20.
Local field potentials (LFP), specifically beta (13-30Hz) frequency measures, have been found to be associated with motor dysfunction in people with Parkinson's disease (PwPD). A consensus on beta subband (low- and high-beta) relationships to clinical state or therapy response has yet to be determined. The objective of this review is to synthesize literature reporting the association of low- and high-beta characteristics to clinical ratings of motor symptoms in PwPD.
A systematic search of existing literature was completed using EMBASE. Articles which collected subthalamic nucleus (STN) LFPs using macroelectrodes in PwPD, analyzed low- (13-20 Hz) and high-beta (21-35 Hz) bands, collected UPDRS-III, and reported correlational strength or predictive capacity of LFPs to UPDRS-III scores.
The initial search yielded 234 articles, with 11 articles achieving inclusion. Beta measures included power spectral density, peak characteristics, and burst characteristics. High-beta was a significant predictor of UPDRS-III responses to therapy in 5 (100%) articles. Low-beta was significantly associated with UPDRS-III total score in 3 (60%) articles. Low- and high-beta associations to UPDRS-III subscores were mixed.
This systematic review reinforces previous reports that beta band oscillatory measures demonstrate a consistent relationship to Parkinsonian motor symptoms and ability to predict motor response to therapy. Specifically, high-beta, demonstrated a consistent ability to predict UPDRS-III responses to common PD therapies, while low-beta measures were associated with general Parkinsonian symptom severity. Continued research is needed to determine which beta subband demonstrates the greatest association to motor symptom subtypes and potentially offers clinical utility toward LFP-guided DBS programming and adaptive DBS.
局部场电位（LFP），特别是β（13-30Hz）频段的测量，与帕金森病患者（PwPD）的运动功能障碍有关。但β子带（低β和高β）与临床状态或治疗反应的关系尚未达成共识。本综述的目的是综合分析报告帕金森病患者 LFP 与运动症状临床评分相关的低β和高β特征的文献。
使用 EMBASE 完成了对现有文献的系统搜索。文章使用微电极收集 PwPD 的丘脑底核（STN）LFP，分析低β（13-20Hz）和高β（21-35Hz）频段，收集 UPDRS-III，并报告 LFP 与 UPDRS-III 评分的相关强度或预测能力。
初始搜索产生了 234 篇文章，其中 11 篇符合纳入标准。β 测量指标包括功率谱密度、峰值特征和爆发特征。高β是 5 篇（100%）文章中治疗反应 UPDRS-III 的显著预测因子。低β与 3 篇（60%）文章的 UPDRS-III 总分显著相关。低β和高β与 UPDRS-III 子评分的关联存在差异。
本系统综述证实了先前的报告，即β频带振荡测量与帕金森运动症状和预测治疗对运动反应的能力之间存在一致的关系。具体而言，高β一致地能够预测 UPDRS-III 对常见 PD 治疗的反应，而低β测量值与一般帕金森病症状严重程度相关。需要进一步研究以确定哪个β子带与运动症状亚型的相关性最大，并可能为 LFP 引导的 DBS 编程和自适应 DBS 提供临床实用性。
